Down again today after yesterday's crash. 8.75% was an institution selling. Their business model is broken. They weren't making money with a good reimbursement code, much less the revised one. And there's zero room for international growth as the reimbursement isn't even as generous as Novitas. Again, I wouldn't short the stock as someone might finally catch on to what the future of the industry is and make some smart acquisitions, but I haven't seen any sign of it from anyone in charge over there.
R
Chart no looking good. Down 80% ytd and each week new low... Still way overvalued so has long way to go. They have to make drastic cuts!! Totally bloated Company. CMS has spoken for 2022, so they need to do something asap.
A
The trap door is now open. On the way to $50/share then to $27/share as 3Q2021 has begun.
J
What's good entry for this company. How are they running business without making money for years ?
R
Tough to look at the losses some of these investors have had with this company. Some of the large ones are down a couple to few 100millions! Not the brightest to invest in medical company with out a real/established billing code.. Lesson learned??
R
CMS already spoke for 2022. No changes for you!! LOL, told them to try for other MACS... Yeah, like another MAC wants to pay out millions to them. They did it to themselves bragging and catering to stock market with 76% margins. Don't cry now that CMS won't pay 76% margins.
n
Board of Directors - It appears that all of the VCs have abandoned ship in the last few months. Looks like the choice of CEO is going to require "Devine" intervention at this stage!
S
good time to entry buy?
C
Just ate some more stocks... nom nom nom.... so much up side here!!!
Bullish
j
SEC really should look into this stock
C
This board is full of paid bears helping market makers to accumulate shares. Well done bears.
Neutral
L
Yahoo is overall bearish? time to load up with shares then 🚀 just do the opposite of what people tell you to do on here usually.
L
Does anybody know if their product actually works? I guess ex-CEO doesn't think so.
M
It’ll rebound a little tmr! Make sure to escape as early as possible tmr!
Bearish
A
Rats are fleeing the sinking ship ahead of plunging 3Q2021 numbers.
T
full recovery and then up for the day, this is good news
A
Is this a buy today? I think it cannot go lower than this! 64-65$ is the bottom.
B
With $200 mil revenue and $3-4 loss. This is not more than 12-13, but be generous then $20-30. Rest is all fat. Fired CEO n then investigation. Long shot $12-13. I am here.
S
I suggest people read the public 10-Q quarterly report just submitted by IRTC May 10th, 2021 to the SEC before considering to purchase this stock. In this report, there is much concern to be read. They expressly state that they have a history of net loss, whey they do expect to continue. They also state they may not be able to achieve or sustain profitability in the future. They have incurred net losses since their inception.
Down again today after yesterday's crash. 8.75% was an institution selling. Their business model is broken. They weren't making money with a good reimbursement code, much less the revised one. And there's zero room for international growth as the reimbursement isn't even as generous as Novitas. Again, I wouldn't short the stock as someone might finally catch on to what the future of the industry is and make some smart acquisitions, but I haven't seen any sign of it from anyone in charge over there.
On the way to $50/share then to $27/share as 3Q2021 has begun.